Skip to main content
FOCIS 2023 Main banner
Final Program


Scientific Program
Back
ViewAttendees 6

Session: ImmunoOncology

Mechanisms Driving CAR T Cells

Wednesday, June 21, 2023
9:10 AM – 9:35 AM  
Location: Salon F-G

    Speaker(s)

  • Marcela Maus, MD, PhD

    Marcela V. Maus, MD, PhD Paula O’Keefe Associate Professor of Medicine Director, Cellular Immunotherapy Program MGH Cancer Center and Harvard Medical School Associate Member, Broad Institute of Harvard and MIT
    Massachusetts General Hospital Cancer Center

Disclosure(s):
Marcela Maus, MD, PhD: 2Seventy Bio: Consultant/Advisor (Ongoing); Adaptimmune, Agenus, Allogene, Arcellx, Astellas, AstraZeneca, Atara, Bayer, BMS, Cabaletta Bio (SAB), Cellectis (SAB), CRISPR therapeutics, EMD Serono, Genocea, In8bio (SAB), Intellia, GSK, Kite Pharma, Micromedicine/BendBio, Neximmune, Novartis, On: Consultant/Advisor (Ongoing); Century Therapeutics, Genocea, Oncternal, TCR2, 2Seventy Bio: Equity/Owner (Ongoing); Kite Pharma, Servier, Novartis: Grant Support (Ongoing); Marcela V. Maus, MD., PhD, is an inventor on patents related to adoptive cell therapies, held by Massachusetts General Hospital and University of Pennsylvania (some licensed to Novartis). MVM holds equity in TCR2, Century Therapeutics, Genocea, Oncte: Patents/Royalty (Ongoing)

Learning Objectives:

  • Understand the role of IFNg in CAR T cells.
  • Understand the role of Tregs in CAR T cells.
  • Understand the role of adhesion.